[go: up one dir, main page]

NO20030474D0 - Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel - Google Patents

Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel

Info

Publication number
NO20030474D0
NO20030474D0 NO20030474A NO20030474A NO20030474D0 NO 20030474 D0 NO20030474 D0 NO 20030474D0 NO 20030474 A NO20030474 A NO 20030474A NO 20030474 A NO20030474 A NO 20030474A NO 20030474 D0 NO20030474 D0 NO 20030474D0
Authority
NO
Norway
Prior art keywords
aryl
active ingredient
drug containing
dementia drug
oxodihydropurine derivatives
Prior art date
Application number
NO20030474A
Other languages
English (en)
Other versions
NO20030474L (no
Inventor
Kiyoshi Furukawa
Satoshi Kurumiya
Takashi Hashimoto
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of NO20030474D0 publication Critical patent/NO20030474D0/no
Publication of NO20030474L publication Critical patent/NO20030474L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20030474A 2000-07-31 2003-01-30 Legemiddel mot demens inneholdende 2-aryl-8- oksodihydropurinderivater som aktiv bestanddel NO20030474L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000230209 2000-07-31
PCT/JP2001/006363 WO2002010167A1 (fr) 2000-07-31 2001-07-24 Medicaments contre la demence contenant des derives de 2-aryl-8-oxodihydropurine comme ingredient actif

Publications (2)

Publication Number Publication Date
NO20030474D0 true NO20030474D0 (no) 2003-01-30
NO20030474L NO20030474L (no) 2003-03-27

Family

ID=18723200

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030474A NO20030474L (no) 2000-07-31 2003-01-30 Legemiddel mot demens inneholdende 2-aryl-8- oksodihydropurinderivater som aktiv bestanddel

Country Status (19)

Country Link
US (1) US6962921B2 (no)
EP (1) EP1306378A4 (no)
KR (1) KR100829297B1 (no)
CN (1) CN1247578C (no)
AU (1) AU7278701A (no)
BR (1) BR0112881A (no)
CA (1) CA2416706C (no)
CZ (1) CZ2003234A3 (no)
HK (1) HK1054231A1 (no)
HU (1) HUP0303714A3 (no)
IL (1) IL154049A0 (no)
MX (1) MXPA03000861A (no)
NO (1) NO20030474L (no)
NZ (1) NZ523812A (no)
PL (1) PL363870A1 (no)
RU (1) RU2277096C2 (no)
SK (1) SK1292003A3 (no)
WO (1) WO2002010167A1 (no)
ZA (1) ZA200300549B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7760101B2 (en) * 2008-06-20 2010-07-20 Kimberly-Clark Worldwide, Inc. Method of reducing sensor corrosion in absorbent articles
KR101820541B1 (ko) * 2009-09-09 2018-02-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 8-옥소디히드로퓨린 유도체
EP2718464A1 (en) 2011-06-06 2014-04-16 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453428A (en) * 1991-02-14 1995-09-26 The Mount Sinai School Of Medicine Of The City Of New York Method and composition for the treatment of apathy-amotivation syndrome
EP1022025A3 (en) * 1991-06-26 2002-06-05 Sepracor, Inc. Method and compositions for treating emesis nausea and other disorders using optically pure R(+) ondansetron
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
NZ329798A (en) 1996-07-03 1999-04-29 Japan Energy Corp Purine derivatives their tautomers and salts thereof and interferon secretion inducers, antiviral agents and anticancer drugs containing the same
ZA9810490B (en) * 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP3814125B2 (ja) * 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬

Also Published As

Publication number Publication date
BR0112881A (pt) 2003-07-01
HUP0303714A2 (hu) 2004-03-01
US6962921B2 (en) 2005-11-08
ZA200300549B (en) 2003-08-19
IL154049A0 (en) 2003-07-31
RU2277096C2 (ru) 2006-05-27
WO2002010167A1 (fr) 2002-02-07
PL363870A1 (en) 2004-11-29
MXPA03000861A (es) 2004-04-05
KR100829297B1 (ko) 2008-05-13
CA2416706C (en) 2009-04-07
CA2416706A1 (en) 2002-02-07
CN1247578C (zh) 2006-03-29
SK1292003A3 (en) 2003-08-05
NZ523812A (en) 2004-07-30
EP1306378A1 (en) 2003-05-02
HUP0303714A3 (en) 2007-03-28
KR20030019634A (ko) 2003-03-06
HK1054231A1 (zh) 2003-11-21
CZ2003234A3 (cs) 2003-05-14
NO20030474L (no) 2003-03-27
AU7278701A (en) 2002-02-13
EP1306378A4 (en) 2005-02-09
CN1466587A (zh) 2004-01-07
US20030166667A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
NO20034149D0 (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
ITTO20010005A0 (it) Formulazione farmaceutica.
NO20024175D0 (no) Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20032909D0 (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
FR2804025B1 (fr) Compositions pharmaceutiques stabilisees
IL161940A0 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
MXPA03001425A (es) Compuestos farmaceuticos.
NO20014926L (no) Farmasöytiske forbindelser
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
NO20020457L (no) Benzenaminderivater som antikoagulanter
NO20054214D0 (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
AR025867A1 (es) Formulacion portasdora farmaceutica
NO20030474D0 (no) Demens-legemiddel som inneholder 2-aryl-8- oksodihydropurinderivater som denaktive bestanddel
NO20004816D0 (no) Ny farmasøytisk formulering
EE200300045A (et) Kristalne ravimaine
NO20041878L (no) Karboksylsyrederivat-forbindelser og legemidler inneholdende de samme som den aktive bestanddel.
AU2001242819A1 (en) Pharmaceutical compositions containing as the active ingredient nitropyrimidine derivatives or salts thereof
AU2001272787B2 (en) Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application